Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Savara Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

YARDLEY, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE GRANT OF INDUCEMENT AWARDS TO NEW EMPLOYEES. ON AUGUST 17, 2026, THE COMPENSATION COMMITTEE OF SAVARA'S BOARD OF DIRECTORS GRANTED THE INDUCEMENT AWARDS TO EIGHT NEW EMPLOYEES WHO RECENTLY JOINED THE COMPANY. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE 74,500 SHARES OF THE COMPANY'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS).

SAVARA ANNOUNCES NEW EMPLOYMENT INDUCEMENT GRANT

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDING JUNE 30, 2026 AND PROVIDED A BUSINESS UPDATE. WHILE WE HAVE REGULATORY APPLICATIONS UNDER REVIEW ACROSS THE U.S., EU, AND U.K., THE U.S. REPRESENTS OUR NEAREST-TERM OPPORTUNITY, SAID MATT PAULS, J.D., M.B.A., CHAIR AND CHIEF EXECUTIVE OFFICER, SAVARA. OUR FOCUS IS ON THE POTENTIAL L.

SAVARA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THAT THE EUROPEAN PATENT OFFICE (EPO) HAS GRANTED A PATENT COVERING THE LIQUID FORMULATION OF MOLBREEVI, AN ORALLY INHALED RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF). EUROPEAN PATENT NO.4121000 PROVIDES PROTECTION FOR MOLBREEVI THROUGH MARCH 2041. SEPARATELY, THE AUSTRALIAN PATENT OFFICE HAS A.

SAVARA ANNOUNCES EUROPEAN AND AUSTRALIAN PATENT OFFICES HAVE GRANTED PATENTS FOR THE LIQUID FORMULATION OF MOLBREEVI*, PROVIDING PROTECTION IN EUROPE AND AUSTRALIA UNTIL MARCH 2041

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE GRANT OF INDUCEMENT AWARDS TO NEW EMPLOYEES. ON JUNE 11, 2026, THE COMPENSATION COMMITTEE OF SAVARA'S BOARD OF DIRECTORS GRANTED THE INDUCEMENT AWARDS TO FOUR NEW EMPLOYEES WHO RECENTLY JOINED THE COMPANY. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE 36,500 SHARES OF THE COMPANY'S COMMON STOCK, RESTRICTED STOCK UNITS (RSUS) COV.

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THAT DAVE LOWRANCE, CHIEF FINANCIAL AND ADMINISTRATIVE OFFICER, IS STEPPING DOWN FROM HIS ROLE FOR HEALTH-RELATED REASONS, EFFECTIVE JULY 15, 2026. AS PART OF THIS TRANSITION, THE FINANCIAL AND ADMINISTRATIVE RESPONSIBILITIES OF THE ROLE WILL BE SEPARATED GOING FORWARD. ROBERT LUTZ, M.B.A., THE COMPANY'S CHIEF OPERATING OFFIC.

SAVARA ANNOUNCES CHIEF FINANCIAL AND ADMINISTRATIVE OFFICER TRANSITION

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM WILL HOST ONE-ON-ONE MEETINGS AND PARTICIPATE IN A FIRESIDE CHAT AT THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 3RD AT 11:05AM ET IN NEW YORK, NY. THE LIVE WEBCAST AND SUBSEQUENT REPLAY WILL BE AVAILABLE ON THE EVENTS & PRESENTATIONS SECTION OF THE COMPANY'S C.

SAVARA ANNOUNCES PARTICIPATION IN THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, PRESENTED A POSTER AT THE ATS 2026 INTERNATIONAL CONFERENCE THAT IS TAKING PLACE MAY 15-20, 2026, IN ORLANDO, FLORIDA. THE POSTER REPORTED NEW BIOMARKER DATA FROM THE DOUBLE-BLIND PERIOD OF THE IMPALA-2 PHASE 3 CLINICAL TRIAL EVALUATING MOLGRAMOSTIM FOR THE TREATMENT OF APAP. BELOW IS A SUMMARY OF THE POSTER PRESENTED. POSTER BOARD 401: REL.

SAVARA PRESENTED NEW BIOMARKER DATA FROM THE IMPALA-2 PHASE 3 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT THE AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE 2026

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, PRESENTED A POSTER AT THE ATS 2026 INTERNATIONAL CONFERENCE THAT IS TAKING PLACE MAY 15-20, 2026, IN ORLANDO, FLORIDA. THE POSTER REPORTS LONG-TERM EFFICACY AND SAFETY DATA FROM THE FIRST 48 WEEKS OF THE ONGOING OL TREATMENT PERIOD OF THE IMPALA-2 PHASE 3 CLINICAL TRIAL EVALUATING MOLGRAMOSTIM FOR THE TREATMENT OF APAP. IMPALA-2 IS THE LONGE.

SAVARA PRESENTED LONG-TERM EFFICACY AND SAFETY DATA FROM THE ONGOING IMPALA-2 PHASE 3 CLINICAL TRIAL OPEN-LABEL (OL) EXTENSION OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, SPONSORED AN ORAL PRESENTATION AT THE ATS 2026 INTERNATIONAL CONFERENCE THAT IS TAKING PLACE MAY 15-20, 2026, IN ORLANDO, FLORIDA. THE PRESENTATION REPORTED NEW EXERCISE CAPACITY DATA FROM THE DOUBLE-BLIND PERIOD OF THE IMPALA-2 PHASE 3 CLINICAL TRIAL EVALUATING MOLGRAMOSTIM FOR THE TREATMENT OF APAP. BELOW IS A SUMMARY OF THE DATA PRESENTED.

SAVARA ANNOUNCES NEW EXERCISE CAPACITY DATA FROM THE IMPALA-2 PHASE 3 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDING MARCH 31, 2026 AND PROVIDED A BUSINESS UPDATE. "WITH APPROXIMATELY $203 MILLION IN CASH AND, UPON MOLBREEVI APPROVAL, ACCESS TO UP TO AN ADDITIONAL $150 MILLION IN NON-DILUTIVE CAPITAL THROUGH DEBT AND ROYALTY STRUCTURES, WE REMAIN WELL CAPITALIZED TO FUND GLOBAL COMMERCIAL LAUNCH PREPA.

Savara Inc.

SVRA

Price

Financial Reports

No items found.

Press Releases

Savara Inc.

SVRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SVRA